Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers

Ahmad Al‐Attar(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Lucy Gossage(Nottingham University Hospitals NHS Trust), M. Mohammed(University of Nottingham), Stephen Chan(Heidelberg University), Rachel Abbotts(University of Nottingham), Mohamed Shehata(Nottingham University Hospitals NHS Trust), Irshad Soomro, Dileep N. Lobo(Nottingham University Hospitals NHS Trust), Khaleel Fareed(University of Nottingham), Abed M. Zaitoun(GlaxoSmithKline (United Kingdom))
British Journal of Cancer
January 19, 2010
10.1038/sj.bjc.6605541
Cited by 111

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605